Looking to clarify its expectations for manufacturer responses following inspections, the FDA earlier this year unveiled, for the first time, draft guidance on best practices for the industry when replying to the receipt of a Form 483.
The proposed guidelines (PDF)—which the FDA is soliciting feedback on through May 8—have the potential to even the odds for newer companies or first-time responders who find themselves in the regulatory crosshairs, and may signal the agency’s desire for more holistic feedback after doling out observations, too.
But the level of responses outlined in the guidance, and the timeframe under which they are expected, introduces a certain level of “tension” that manufacturers ought to address during the public comment period, Sonia Nath, chair of Cooley’s life sciences and healthcare regulatory practice group, said in a recent interview with Fierce. Specifically, a discrepancy lies between the FDA’s good intentions of standardizing practice and what many smaller companies can realistically do, she said.
Issued in March, the FDA’s draft guidance aims to impart the benefit of “concise, factual, and effective corrective action responses” from a company after receiving a Form 483, according to a notice on the Federal Register.
“FDA has previously received inadequate responses to FDA 483 observations due to a lack or omission of relevant data, excessive amounts of data, and/or failure to address the root cause of observations in the FDA 483,” the notice continues, adding that poor quality responses make it harder for the regulator to determine “what the establishment has corrected since the inspection and to evaluate remediation activities.”
The FDA hands out Forms 483 to manufacturers when they identify objectionable conditions or practices concerning agency-regulated products, which could violate the Federal Food, Drug, and Cosmetic Act. Importantly, a Form 483 includes inspection observations but does not represent the FDA’s final conclusions about an establishment’s compliance with good manufacturing practices, the agency explained in the draft guidance.
In some instances, a Form 483 may serve as a prelude to the more serious reprimand of an FDA Warning Letter. Companies do not have to respond to the agency after receiving a Form 483, though it is often considered the best practice to do so, and the guidance would suggest that the FDA is now hoping for more from those replies.
“Up until now, companies have been figuring it out on their own, relying on their own experience and—especially in the case of large pharmas—institutional knowledge,” Nath said in the interview, adding that “there was really no playbook from the FDA.”
In her estimation, the guidance marks an effort by the FDA to “level the playing field a bit—or at least add a little more structure potentially.”
Nath reiterated that larger pharma outfits may have been helping set the standard in their Form 483 responses, enlisting outside counsel “who had a better sense of what ‘good’ looks like in this space,” and who in many cases would also furnish the regulator with interim responses after their initial replies.
In turn, the guidance could serve as a useful resource for newer companies or first-time responders to the FDA that may not “know those rules of the road,” she said.
FDA sets expectations
Broadly speaking, the draft guidance covers the logistics of actually submitting a response, recommendations on what shape those responses should take and, lastly, best practices for resolving scientific or technical disagreements a company may have with an observation.
Of note in the initial category, the FDA homed in on the value of interim reporting from Form 483 responders, but it left its own obligations on how it would respond to those updates somewhat unclear.
The agency specifically notes that for remediation actions that aren’t complete by the time of an initial response—which must occur within 15 business days—companies should consider providing preliminary results, interim corrective measures and a prospective timeline on their resolution actions, along with a plan for when they intend to provide interim updates.
In return, the FDA notes it “can review these reports to periodically assess the risk associated with the status of the corrective actions and will take additional actions, in accordance with our applicable authorities, as necessary to protect patient and public health.”
Nath flagged that as a potential point of “tension” in the guidance: Despite discussing the value of interim reporting by company responders, the guidance doesn’t say that the FDA has to consider the interim responses, she pointed out.
“It’s a bit of a give-and-take and, frankly, I think a point of confusion in the current guidance,” Nath said.
Adding to that, she explained that some of the changes companies might want to make would take much longer than the 15-day window during which the FDA allows for a Form 483 response.
Essentially, the issue comes down to communication, and specifically, how the FDA should be expected to weigh and reply to interim responses, should companies provide them, per Nath.
In its guidance, the FDA stressed that it “will not ordinarily delay regulatory action, such as issuing a warning letter, to review a response to an FDA 483 that is received more than 15 business days after the FDA 483 was issued.”
As for the depth of the responses outlined in the guidance, the FDA appears to be seeking out more holistic replies from the industry, and how those responses tie back into companies’ overall quality systems, Nath explained.
In the draft document, the FDA notes that companies should weigh the severity of observations and prioritize corrective actions accordingly. The agency also states that companies would do well to determine if deficiencies described in the Form 483 could extend to other drugs, processes or facilities.
In some ways, the level of response articulated in the 483 guidance aligns more closely with what a company might normally expect after receipt of a warning letter, Nath pointed out.
“These are just observations, not conclusions,” she said of a 483 write-up.
“Again, I think there is a tension here between wanting more structure and wanting to make sure industry is aware of things like interim responses,” Nath said. “But in doing so, they may be raising the bar at the inspection level beyond what was intended and what many companies—especially smaller to medium-sized companies—can realistically do in the 15-day business window.”
As for how companies should be steeling for future site visits following the guidance’s release, Nath said that the agency communication likely represents “a call to industry that there’s going to be increased regulatory scrutiny on inspections.”